Arcturus Therapeutics
ARCT
116 hedge funds and large institutions have $328M invested in Arcturus Therapeutics in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 40 reducing their positions, and 26 closing their positions.
57% more call options, than puts
Call options by funds: $5.48M | Put options by funds: $3.48M
0.45% less ownership
Funds ownership: 83.85% → 83.4% (-0.45%)
5% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 40
7% less capital invested
Capital invested by funds: $354M → $328M (-$25.5M)
9% less funds holding
Funds holding: 128 → 116 (-12)
46% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 26
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$14.7M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$5.51M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.13M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.97M |
| 2 |
Morgan Stanley
New York
|
-$3.82M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$3.79M |
| 4 |
Millennium Management
New York
|
-$3.12M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$2.05M |
ARCT Hedge Fund Activity: Q3 2022 in Review
116 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q3 2022, worth a combined $328M — down 7.2% from $354M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ARCT and 14 opened new positions — a net loss of 12 holders — while 40 trimmed existing stakes and 38 added.
The largest buyer was Woodline Partners, opening a new position worth an estimated $14.7M. The largest seller was Point72 Asset Management, cutting an estimated $4.97M.
- 116 institutional investors held Arcturus Therapeutics (ARCT) as of Q3 2022, down from 128 in Q2 2022.
- Funds reported $328M of Arcturus Therapeutics stock for Q3 2022, down 7.2% quarter-over-quarter.
- 14 funds opened new Arcturus Therapeutics positions in Q3 2022 and 26 closed out, a net change of -12 holders.
- The largest Arcturus Therapeutics buyer in Q3 2022 was Woodline Partners, an estimated $14.7M added.
- The largest Arcturus Therapeutics seller in Q3 2022 was Point72 Asset Management, an estimated $4.97M sold.
Based on aggregated 13F filings for Q3 2022.